GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Debt-to-Asset

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Debt-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Debt-to-Asset?

Telomir Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Telomir Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Telomir Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $3.50 Mil. Telomir Pharmaceuticals's debt to asset for the quarter that ended in Mar. 2024 was 0.00.


Telomir Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Telomir Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Debt-to-Asset Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Asset
- - 0.02

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only - 0.08 0.25 0.02 -

Competitive Comparison of Telomir Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Telomir Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telomir Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's Debt-to-Asset falls into.



Telomir Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Telomir Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Telomir Pharmaceuticals's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telomir Pharmaceuticals  (NAS:TELO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Telomir Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines